Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79


Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer.

Hsu DS, Acharya CR, Balakumaran BS, Riedel RF, Kim MK, Stevenson M, Tuchman S, Mukherjee S, Barry W, Dressman HK, Nevins JR, Powers S, Mu D, Potti A.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5312-7. doi: 10.1073/pnas.0900827106. Epub 2009 Mar 11. Erratum in: Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):14705.


Both gene amplification and allelic loss occur at 14q13.3 in lung cancer.

Harris T, Pan Q, Sironi J, Lutz D, Tian J, Sapkar J, Perez-Soler R, Keller S, Locker J.

Clin Cancer Res. 2011 Feb 15;17(4):690-9. doi: 10.1158/1078-0432.CCR-10-1892. Epub 2010 Dec 10.


Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer.

Kendall J, Liu Q, Bakleh A, Krasnitz A, Nguyen KC, Lakshmi B, Gerald WL, Powers S, Mu D.

Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16663-8. Epub 2007 Oct 9.


Functional analysis of Nkx2.1 and Pax9 for calcitonin gene transcription.

Suzuki M, Katagiri N, Ueda M, Tanaka S.

Gen Comp Endocrinol. 2007 Jun-Jul;152(2-3):259-66. Epub 2007 Feb 28.


Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer.

Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M, Miyake M.

Cancer Res. 1996 Apr 15;56(8):1751-5.


[Study of prognostic factors in patients with stage I non-small cell lung cancer].

Jiang ZQ, Jiang GL, Shi DR, Zhang RX, Fu XL, Qian H.

Zhonghua Zhong Liu Za Zhi. 2004 Jun;26(6):364-8. Chinese.


Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma.

Puglisi F, Barbone F, Damante G, Bruckbauer M, Di Lauro V, Beltrami CA, Di Loreto C.

Mod Pathol. 1999 Mar;12(3):318-24.


Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.

Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC, Harris AL.

Br J Cancer. 2001 Sep 14;85(6):881-90.


[Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].

Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L.

Ai Zheng. 2004 Jul;23(7):845-50. Chinese.


Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.

Jeong SH, Jung JH, Han JH, Kim JH, Choi YW, Lee HW, Kang SY, Hwang YH, Ahn MS, Choi JH, Oh YT, Chun M, Kang S, Park KJ, Hwang SC, Sheen SS.

Lung Cancer. 2010 May;68(2):288-94. doi: 10.1016/j.lungcan.2009.06.003. Epub 2009 Jun 27.


Associations of deregulation of mir-365 and its target mRNA TTF-1 and survival in patients with NSCLC.

Sun R, Liu Z, Ma G, Lv W, Zhao X, Lei G, Xu C.

Int J Clin Exp Pathol. 2015 Mar 1;8(3):2392-9. eCollection 2015.


Prognostic significance of allelic imbalances on chromosome 9p in stage I non-small cell lung carcinoma.

Tomizawa Y, Adachi J, Kohno T, Hamada K, Saito R, Noguchi M, Matsuno Y, Hirohashi S, Yamaguchi N, Yokota J.

Clin Cancer Res. 1999 May;5(5):1139-46.


Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung.

O-charoenrat P, Rusch V, Talbot SG, Sarkaria I, Viale A, Socci N, Ngai I, Rao P, Singh B.

Clin Cancer Res. 2004 Sep 1;10(17):5792-803.


Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.

De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, Lehtiö J.

Lung Cancer. 2009 Mar;63(3):410-7. doi: 10.1016/j.lungcan.2008.06.003. Epub 2008 Jul 11.


Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer.

Castillo SD, Angulo B, Suarez-Gauthier A, Melchor L, Medina PP, Sanchez-Verde L, Torres-Lanzas J, Pita G, Benitez J, Sanchez-Cespedes M.

J Pathol. 2010 Sep;222(1):89-98. doi: 10.1002/path.2732.


A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer.

Yanagisawa K, Tomida S, Shimada Y, Yatabe Y, Mitsudomi T, Takahashi T.

J Natl Cancer Inst. 2007 Jun 6;99(11):858-67.


An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer.

Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, Witteveen AT, Rzyman W, Floore A, Burgers S, Giaccone G, Meister M, Dienemann H, Skrzypski M, Kozlowski M, Mooi WJ, van Zandwijk N.

Clin Cancer Res. 2009 Jan 1;15(1):284-90. doi: 10.1158/1078-0432.CCR-08-1258.


Thyroid transcription factor 1 represses the expression of Ki-67 and induces apoptosis in non-small cell lung cancer.

Zu YF, Wang XC, Chen Y, Wang JY, Liu X, Li X, Li CW, Xie YC, Luo Y, Shang XQ, Guo J.

Oncol Rep. 2012 Nov;28(5):1544-50. doi: 10.3892/or.2012.2009. Epub 2012 Aug 31.


Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.

Saito K, Kawakami K, Matsumoto I, Oda M, Watanabe G, Minamoto T.

Clin Cancer Res. 2010 Apr 15;16(8):2418-26. doi: 10.1158/1078-0432.CCR-09-2819. Epub 2010 Apr 6.


Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection.

Broët P, Camilleri-Broët S, Zhang S, Alifano M, Bangarusamy D, Battistella M, Wu Y, Tuefferd M, Régnard JF, Lim E, Tan P, Miller LD.

Cancer Res. 2009 Feb 1;69(3):1055-62. doi: 10.1158/0008-5472.CAN-08-1116. Epub 2009 Jan 27.

Supplemental Content

Support Center